<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01434225</url>
  </required_header>
  <id_info>
    <org_study_id>08NR26</org_study_id>
    <nct_id>NCT01434225</nct_id>
  </id_info>
  <brief_title>NEMO1:NEonatal Seizure Using Medication Off-patent</brief_title>
  <acronym>NEMO1</acronym>
  <official_title>NEMO1: An Open Label Exploratory Dose Finding and Pharmacokinetic Clinical Trial of Bumetanide for the Treatment of Neonatal Seizure Using Medication Off-patent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Only For Children Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cork University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Hospitals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Great Ormond Street Hospital for Children NHS Foundation Trust</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Ireland: Research Ethics Committee</authority>
    <authority>Ireland: Irish Medicines Board</authority>
    <authority>Finland: Ethics Committee</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Netherlands: Medicines Evaluation Board (MEB)</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NEMO is a multicentre pan European clinical trial with the aim to develop new treatment
      strategies for the treatment of neonatal seizures using the loop diuretic bumetanide. There
      is evidence that bumetanide improves GABAergic function of the current standard drug,
      phenobarbitone. Bumetanide has been used as a diuretic in term and preterm babies for around
      thirty years. This trial should confirm that Bumetanide in addition to standard treatment
      will result in better seizures control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Optimal dose finding</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The optimal dose is defined as achieving effective seizure reduction:
Reduction of electrographic seizure (measuresd by EEG) burden by &gt;80% during the 3rd and 4th hour after the first bumetanide administration compared to a 2 hour epoch prior to Bumetanide administration.
No need for rescue AED within 48 hours</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Neonatal Seizures</condition>
  <arm_group>
    <arm_group_label>Bumetanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide</intervention_name>
    <description>Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).</description>
    <arm_group_label>Bumetanide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:-

          -  Male or female term baby with gestational age of 37-43 weeks and postnatal age &lt;48
             hours

          -  One or more of the following:

          -  APGAR score &lt; 5 at 5 mins.

          -  Umbilical cord or first arterial blood sample pH &lt; 7.1 or base deficit &gt;16 mmol/L.

          -  Postnatal resuscitation still required 10 minutes after birth

               -  Clinically evolving encephalopathy

               -  Received one dose of standard anticonvulsive therapy (phenobarbitone,20mg/kg)
                  for clinical or electrographic seizures.

               -  EEG: equal to or more than 3 min cumulative seizures, or 2 or more seizures of
                  &gt;30 sec duration over 2 hr period within first 48 hr of life

               -  Written informed consent of parent or guardian.

               -  EEG monitoring has commenced within the first 48 hours of birth.

        Exclusion Criteria:

          -  Suspected or confirmed brain malformation, inborn error of metabolism,genetic
             syndrome, or major congenial malformation

          -  Congenital (in utero) infection (TORCH).

               -  Babies who have received diuretics such as furosemide or bumetanide in routine
                  clinical management within the last 24 hours.

               -  Total serum bilirubin &gt; 15 mg/dl (255 micromol/l) at inclusion.

               -  On any other anticonvulsive medication other than phenobarbitone or bolus of
                  midazolam / pentobarbitone for intubation.

               -  Anuria/renal failure defined as serum creatinine &gt; 200 micromol/l.

               -  Severe electrolyte depletion (Na &lt;120 mmol/L, K &lt;3.0 mmol/L)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronit Pressler, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Great Ormond Street Hospital for Children NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cork University Maternity Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Universitair Medisch Centrum Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet and University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.nemo-europe.com/</url>
    <description>Study web site</description>
  </link>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 11, 2015</lastchanged_date>
  <firstreceived_date>September 9, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neonatal seizures</keyword>
  <keyword>Hypoxic Ischemic Encephalopathy</keyword>
  <keyword>Electroencephalography</keyword>
  <keyword>Bumetanide</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
